ArticleCardiology research2026
Nuclear Respiratory Factor-1 Ameliorates Heart Failure by Suppressing Cardiomyocyte Pyroptosis-Associated Signaling Via the Downregulation of Gasdermin D and Caspase-1.
Article in Cardiology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiac diseases caused by various factors eventually lead to heart failure (HF) as the condition progresses, during which inflammation and pyroptosis are markedly enhanced. Nuclear respiratory factor-1 (NRF-1) is a transcriptional regulator involved in multiple physiological functions; however, its role in pyroptosis during HF remains unclear. Methods: Serum samples from patients with HF were collected to evaluate the levels of NRF-1. An HF rat model was established to assess the expression of NRF-1 in serum and cardiac tissue and to investigate its association with HF and the expression of inflammatory markers gasdermin D (GSDMD), caspase-1, interleukin (IL)-8, and IL-1β. NRF-1-overexpressing and NRF-1-silenced H9C2 cell lines were constructed, and myocardial injury was induced by hypoxia and doxorubicin (DOX) to evaluate the effects of NRF-1 on pyroptosis-related molecules GSDMD and caspase-1, as well as inflammatory cytokines IL-8 and IL-1β. Finally, the expression of NRF-1 in the serum of HF patients was analyzed based on New York Heart Association (NYHA) functional classification to validate the dynamic changes of NRF-1 during pyroptosis in HF. Results: Although previous studies have reported inconsistent findings regarding serum NRF-1 expression levels among different HF patient cohorts, our current results demonstrate that serum NRF-1 expression is significantly reduced in HF patients compared to those with normal cardiac function (NF), while the expression of pyroptosis-related molecules GSDMD and caspase-1, as well as pro-inflammatory cytokines IL-8 and IL-1β, is markedly increased. These findings were further validated in an HF rat model. Conclusions: NRF-1 is a dynamically expressed molecule with cardioprotective properties that ameliorates HF and attenuates pyroptosis by inhibiting the caspase-1/GSDMD signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.